Abstract

The complement system plays a role in the formation of sub-retinal pigment epithelial (RPE) deposits in early stages of age-related macular degeneration (AMD). But the specific mechanisms that connect complement activation and deposit formation in AMD patients are unknown, which limits the development of efficient therapies to reduce or stop disease progression. We have previously demonstrated that C3 blockage prevents the formation of sub-RPE deposits in a mouse model of EFEMP1-associated macular degeneration. In this study, we have used double mutant Efemp1R345W/R345W:C5-/- mice to investigate the role of C5 in the formation of sub-RPE deposits in vivo and in vitro. The data revealed that the genetic ablation of C5 does not eliminate the formation of sub-RPE deposits. Contrarily, the absence of C5 in RPE cultures promotes complement dysregulation that results in increased activation of C3, which likely contributes to deposit formation even in the absence of EFEMP1-R345W mutant protein. The results also suggest that genetic ablation of C5 alters the extracellular matrix turnover through an effect on matrix metalloproteinases in RPE cell cultures. These results confirm that C3 rather than C5 could be an effective therapeutic target to treat early AMD.

Highlights

  • Age-related macular degeneration (AMD) is the most common cause of visual impairment in developed ­countries[1]

  • We have demonstrated that mice carrying the mutation p.R345W in Efemp[1] recapitulate the formation of basal deposits underneath the retinal pigment epithelial (RPE), the composition of which is similar to those deposits observed in patients with this mutation and in age-related macular degeneration (AMD) patients, including increased expression of C3 in the RPE/Bruch’s membrane (BrM) i­nterface[4,5]

  • Ablating C5 did not abolish the formation of basal deposits in Efemp1R345W/ R345W:C5-/- mice, indicating that C5 is not a good target to prevent the formation of sub-RPE deposits caused by the EGFcontaining fibulin-like extracellular matrix protein 1 (EFEMP1)-R345W mutant protein

Read more

Summary

Introduction

Age-related macular degeneration (AMD) is the most common cause of visual impairment in developed ­countries[1]. The mutation p.R345W in Efemp[1] resulted in decreased matrix metalloproteinase (MMP) activity, which leads to altered extracellular matrix (ECM) turnover by Efemp1R345W/R345W RPE c­ ells[6,15] Such alterations are typically observed in drusen of AMD patients as ­well[16]. Based on our previous research, we hypothesize that downregulation of C3 rather than C5 is required for preventing the formation of basal deposits in early stages of macular ­degenerations[5,6,14,17] To address this question, in the current study we assessed the role of C5 in the formation of sub-RPE deposits in a mouse model of the EFEMP1-associated macular degeneration in vivo and in vitro. Our results show that knocking out C5 is not sufficient to prevent the formation of sub-RPE deposits in Efemp1R345W/R345W mice

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call